Kunming Qi
Impact in
- Oncology top 10%
- CAR-T cell therapy research
- Hematology top 10%
- Hematopoietic Stem Cell Transplantation
- Platelet Disorders and Treatments
Papers in
- Hematology 23
- Hematopoietic Stem Cell Transplantation 7
- Platelet Disorders and Treatments 6
- Multiple Myeloma Research and Treatments 6
- Oncology 19
- CAR-T cell therapy research 13
- Co-authors
- Kailin Xu (52 shared papers)Jianlin Qiao (27 shared papers)Lingyu Zeng (25 shared papers)Hai Cheng (28 shared papers)Jiang Cao (26 shared papers)Junnian Zheng (7 shared papers)Zhenyu Li (11 shared papers)Gang Wang (2 shared papers)
- Journals
- Blood (2 papers)Hematological Oncology (2 papers)Frontiers in Immunology (2 papers)Leukemia Research (2 papers)International Immunopharmacology (2 papers)
- Partner nations
- ChinaUnited StatesPanama
In The Last Decade
Kunming Qi
50 papers receiving 685 citations
Peers
Comparison fields: 5 of 71
- Oncology 362
- Hematology 133
- Immunology 176
- Cancer Research 45
- Genetics 80
Countries citing papers authored by Kunming Qi
This map shows the geographic impact of Kunming Qi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kunming Qi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kunming Qi more than expected).
Fields of papers citing papers by Kunming Qi
This network shows the impact of papers produced by Kunming Qi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kunming Qi. The network helps show where Kunming Qi may publish in the future.
Co-authors
The 25 scholars most cited alongside Kunming Qi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 62 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 130 | |
| 2 | 2021 | 83 | |
| 3 | 2019 | 67 | |
| 4 | Treatment with the C-C chemokine receptor type 5 (CCR5)-inhibitor maraviroc suppresses growth and induces apoptosis of acute lymphoblastic leukemia cells. | 2017 | 31 |
| 5 | 2021 | 27 | |
| 6 | 2018 | 24 | |
| 7 | 2020 | 23 | |
| 8 | 2015 | 21 | |
| 9 | 2016 | 20 | |
| 10 | 2015 | 20 | |
| 11 | 2020 | 19 | |
| 12 | 2016 | 19 | |
| 13 | 2018 | 14 | |
| 14 | 2020 | 13 | |
| 15 | 2018 | 12 | |
| 16 | 2016 | 12 | |
| 17 | 2014 | 12 | |
| 18 | 2015 | 11 | |
| 19 | 2015 | 11 | |
| 20 | 2022 | 10 |
About Kunming Qi
Kunming Qi is a scholar working on Hematology, Oncology, Molecular Biology, Genetics and Immunology, having authored 62 papers that have together received 692 indexed citations. Recurring topics across this work include CAR-T cell therapy research (13 papers), Hematopoietic Stem Cell Transplantation (7 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers), Platelet Disorders and Treatments (6 papers), Multiple Myeloma Research and Treatments (6 papers), Virus-based gene therapy research (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Kruppel-like factors research (3 papers). The work is most often cited by research in Oncology (362 citations), Hematology (133 citations), Immunology (176 citations), Cancer Research (45 citations) and Genetics (80 citations). Kunming Qi has collaborated with scholars based in China, United States and Panama. Frequent co-authors include Kailin Xu, Jianlin Qiao, Lingyu Zeng, Hai Cheng, Jiang Cao, Junnian Zheng, Zhenyu Li, Gang Wang, Wei Sang and Depeng Li. Their work appears in journals such as Blood, Hematological Oncology, Frontiers in Immunology, Leukemia Research and International Immunopharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.